



DIASORIN: A POSITIVE DEBUT ON THE STAR SEGMENT

- Opening price: 12.50 euros;
- High: 13.06 euros;
- Reference price: 12.547 euros;
- Closing price: 12.667 euros;
- Trading volume: 4798000 shares.

Saluggia (Vercelli), July 19, 2007 – The shares of DiaSorin, a company that operates in the global market for in vitro diagnostics developing, producing and marketing reagent kits for laboratory clinical diagnostics, made their debut today on the STAR segment of the Online Stock Market. The shares opened at 12.50 euros, for a gain of 2% over the offering price (12.25 euros per share) and, after an intraday high of 13.06 euros, they closed at 12.667 euros, showing a gain 3.4% over the offering price.

A total of more than 4798000 shares were traded. The corresponding market value was about 61 million euros, equal to 9.6% of total capitalization.

Commenting today's market debut, Carlo Rosa, DiaSorin's Chief Executive Officer, said:

“ This is an extremely important moment for our Company because it represents both an achievement and a step forward along our path toward growth and development. The positive response that we received both during the roadshow and today is evidence of the confidence of investors who responded to our share offering with interest and I am sure will assess our performance based on our ability to deliver on our promises. I am confident that three years hence we will be able to look back to today with the pride that comes from having achieved new and more ambitious goals for our shareholders and our Company.”

* * *

About DiaSorin

DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group comprises 12 companies based in Europe, the United States, Central and South America and Asia. It has about 840 employees, including 70 research and development specialists, and operates three manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany) and Stillwater (USA). Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, thyroid pathologies, oncology, fertility testing, etc.

Contacts:

Laura Villa

DiaSorin S.p.A.

Investor Relations Officer

laura.villa@diasorin.it

+39 0161487532

+39 348 15 11 542

Pasquo Cicchini

Hill & Knowlton

pcicchini@hillandknowlton.com

+39 02 31914245

+39 335 6417880